首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1535835

偏头痛药物市场 - 按药物类别（止痛药 [曲普坦、镇痛药]、预防药 [抗惊厥药、抗忧郁药]）、给药途径（口服、注射）、类型（处方药、非处方药）、配销通路- 全球预测（2024 年 - 2032 年）

Migraine Drugs Market - By Drug Class (Pain Relieving [Triptan, Analgesic], Preventive [Anticonvulsant, Antidepressant]), Route of Administration (Oral, Injectable), Type (Prescription, OTC), Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年06月18日 | 出版商:

Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于人们对改善诊断的认识不断增强以及药物开发的进步，预计 2024 年至 2032 年全球偏头痛药物市场规模的复合年增长率将达到 6.7%。

最近，有些人正在寻求医疗护理并获得准确的诊断，导致对有效治疗的需求更大。同时，研究人员正在透过结合药理学和技术的进步来开发新的偏头痛药物，以增强治疗选择。这些创新正在提高药物疗效，同时减少副作用并提供更有针对性的治疗。例如，2024 年 1 月，Akums 推出了 Lasmiditan 片剂，用于缓解偏头痛症状，以增强治疗选择，从而提供有针对性的方法来管理偏头痛并透过先进的治疗效果改善患者的治疗效果。

偏头痛药物市场按药物类别、给药途径、类型、配销通路和地区划分。

按药物类别划分，由于强烈要求在偏头痛发作之前降低偏头痛发作的频率和严重程度，预计预防性药物领域从 2024 年到 2032 年将以显着的复合年增长率增长。预防性药物的开发和处方是为了控制慢性偏头痛并预防使人衰弱的发作。它们的工作原理是针对引发偏头痛的潜在机制，从而减少攻击的总体发生率和影响。此外，正在进行的研究和技术进步正在完善预防性治疗，为慢性偏头痛患者提供更有效和量身定制的选择。

由于为患者提供更大便利和可及性的需求日益增长，在线药房配销通路领域的偏头痛药物行业价值预计将在 2024 年至 2032 年期间扩大。这些平台提供一系列偏头痛药物，包括处方药和非处方药，进一步允许使用者在家中轻鬆订购和接受治疗。线上药局的日益普及也使个人能够更轻鬆地及时获取药物并更有效地管理他们的治疗计划。

从地区来看，由于医疗保健支出的增加以及对偏头痛疾病的认识和诊断的提高，预计欧洲偏头痛药物行业规模将在 2024 年至 2032 年间激增。公司正在投资先进的治疗方法来支持偏头痛患者。同时，意识的提高和更好的诊断实践正在导致该地区更准确的诊断和对有效偏头痛治疗的更大需求。

产业生态系统分析
产业影响力
- 成长动力
  - 偏头痛的发生率和盛行率不断增加
  - 患者对非侵入性治疗的偏好不断上升
  - 提高对偏头痛的认识和诊断
- 产业陷阱与挑战
  - 严格的监管要求
  - 来自替代疗法的竞争
成长潜力分析
监管环境
管道分析
定价分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪錶板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
止痛药
- 曲普坦类
- 止痛药
- 迪坦斯
- 其他止痛药物
处方药
- 抗惊厥药
- 抗忧郁药
- 乙种肾上腺阻断剂
- CGRP抑制剂
- 其他预防药物

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

主要趋势
口服
可注射
鼻腔
透皮

第 7 章：市场估计与预测：按类型，2021 - 2032

主要趋势
处方药
非处方药

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
药局和零售药局
网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie Inc.
Amgen, Inc.
Astellas Pharma
AstraZeneca Plc
Azurity Pharmaceutical, Inc.
Dr. Reddy's Laboratories, Inc.
Eli Lilly and Company
Endo Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Lannett Company, Inc.
Lundbeck A/S
Pfizer, Inc.
Sanofi SA
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited

简介目录

Product Code: 9899

Global Migraine Drugs Market size is anticipated to witness 6.7% CAGR from 2024 to 2032, due to the increasing awareness for improved diagnosis alongside advancements in drug development.

Lately, several individuals are seeking medical attention and receiving accurate diagnoses, leading to greater demand for effective treatments. Concurrently, researchers are developing new migraine drugs by incorporating advancements in pharmacology and technology to enhance treatment options. These innovations are improving drug efficacy while reducing side effects and providing more targeted therapies. For instance, in January 2024, Akums launched the Lasmiditan tablet to alleviate migraine symptoms to enhance treatment options for providing a targeted approach to managing migraines and improving patient outcomes with advanced therapeutic benefits.

The migraine drugs market is segregated into drug class, route of administration, type, distribution channel, and region.

By drug class, the preventive medication segment is estimated to rise at a significant CAGR from 2024 to 2032 due to the strong requirement to reduce the frequency and severity of migraine attacks before they occur. Preventive medications are developed and prescribed to manage chronic migraines and prevent debilitating episodes. They work by targeting underlying mechanisms that trigger migraines, thereby decreasing the overall occurrence and impact of attacks. Additionally, the ongoing research and technological advancements are refining preventive treatments for more effective and tailored options for individuals with chronic migraines.

Migraine drugs industry value from the online pharmacies distribution channel segment is expected to expand from 2024 to 2032, fueled by the increasing need for offering greater convenience and accessibility for patients. These platforms are providing a range of migraine medications, including both prescription and over-the-counter options, further allowing users to easily order and receive their treatments from home. The growing adoption of online pharmacies is also making it simpler for individuals to access their medications promptly and manage their treatment plans more effectively.

Regionally, the Europe migraine drugs industry size is projected to proliferate between 2024 and 2032, led by rising healthcare expenditure along with increased awareness and diagnosis of migraine disorders. Companies are investing in advanced treatments to support individuals experiencing migraines. Simultaneously, the heightened awareness and better diagnostic practices are leading to more accurate diagnoses and greater demand for effective migraine therapies in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360º synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence and prevalence of migraine
  - 3.2.1.2 Rising patient preference for non-invasive treatment
  - 3.2.1.3 Growing awareness and diagnosis of migraine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Pricing analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Pain relieving medication
- 5.2.1 Triptans
- 5.2.2 Analgesics
- 5.2.3 Ditans
- 5.2.4 Other pain-relieving medications
5.3 Prescription medication
- 5.3.1 Anticonvulsant
- 5.3.2 Antidepressant
- 5.3.3 Beta blocker
- 5.3.4 CGRP inhibitors
- 5.3.5 Other preventive medications

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Nasal
6.5 Transdermal

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Prescription drugs
7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug store & retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa